LarmorBio
LarmorBio is an MIT spinout that develops microscale magnetic resonance (MMR) technology for rapid oxidative stress measurement, serving clinical diagnostics, pharmaceutical drug response monitoring, and bioprocessing applications through its MarlinMR™ and BioScan-NMR™ platforms.
- Company typePrivate
- Founded2021
- HeadquartersAliso Viejo, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What LarmorBio does
LarmorBio is a privately held life science research and clinical diagnostic company founded in 2021 as a Massachusetts Institute of Technology (MIT) spinout, headquartered in Waltham, Massachusetts. The company's core technology is microscale magnetic resonance (MMR), which measures unique properties of the iron redox state in the blood microenvironment as a direct marker of oxidative stress. This platform underpins two branded product lines: MarlinMR™, positioned as a rapid, low-cost, point-of-care oxidative stress test that delivers results in under five minutes from a few drops of blood without specialized training; and BioScan-NMR™, a next-generation NMR diagnostic system targeted for first commercial installation in July 2026 via an exclusive license to Velocity Bioworks.
The company pursues multiple parallel use cases: point-of-care cardiometabolic risk assessment (including a 1,500-patient cardiovascular study at Tan Tock Seng Hospital and a multi-ethnic 350-patient vascular function cohort), pharmaceutical drug response monitoring (GLP-1 effectiveness, cardiac reperfusion injury), and non-invasive bioprocessing monitoring for cell and gene therapy manufacturing (with published R2=0.91 correlation to viable cell density). GTM is enterprise field sales combined with exclusive commercial licensing; revenue mechanics are expected to combine licensing/royalties (Velocity Bioworks), recurring platform access for clinical and bioprocessing deployments, and hardware sales. Validation rests on 19 peer-reviewed publications, a Scientific Advisory Board that includes the technology's inventor (Jongyoon Han, MIT/SMART), and partnerships with Quest Diagnostics, Tan Tock Seng Hospital, Duke-NUS Medical School, and undisclosed pharmaceutical companies.
The company is currently pre-revenue, with 1–10 employees, a freshly expanded executive team (CFO Scott Gleason, CMO Michael McPhaul, board members Emory Anderson and Dean Zikria added March 2025), and a pending Series A financing that is being marketed alongside the July 2026 commercial anchor. Two issued patents and five pending applications protect the core MMR measurement IP.
LarmorBio firmographics
Firmographics- Name
- LarmorBio
- Legal name
- LarmorBio
- Website
- https://larmorbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- LarmorBio is an MIT spinout that develops microscale magnetic resonance (MMR) technology for rapid oxidative stress measurement, serving clinical diagnostics, pharmaceutical drug response monitoring, and bioprocessing applications through its MarlinMR™ and BioScan-NMR™ platforms.
- Ownership category
- akta.pro rank
LarmorBio industry classification
Industry- Product category
- Clinical Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
- akta.pro secondary industries
- Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where LarmorBio is headquartered
LocationHeadquarters
- HQ city
- Aliso Viejo
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
LarmorBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Technology Licensing: Exclusive commercial license agreements with strategic partners such as Velocity Bioworks for the BioScan-NMR platform, positioning partners as demonstration and validation sites for scaled deployment.
- Diagnostic Platform Deployment: Deployment of microscale MR systems globally in partnership with major research hospitals and leading healthcare companies for clinical diagnostics applications.
- Life Science Research Services: Providing researchers with oxidative stress testing and bioprocessing monitoring capabilities through platform access and partnership arrangements.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
LarmorBio product offering
Product offeringCore offering
LarmorBio develops and commercializes Microscale Magnetic Resonance (MMR) technology-based diagnostic platforms — MarlinMR™ for rapid oxidative stress testing and BioScan-NMR™ for next-generation NMR diagnostics — that measure iron redox state in blood samples and enable non-invasive, label-free monitoring of cell health. The platforms deliver results from a few drops of blood in under 5 minutes at low cost, serving clinical diagnostics and life science bioprocessing applications.
Product overview
LarmorBio offers a unified microscale magnetic resonance (MMR) technology platform for life science research and clinical diagnostics. The core offering consists of the MMR Platform, which powers two branded product lines: MarlinMR™ (oxidative stress testing) and BioScan-NMR™ (next-generation NMR diagnostics). The MMR technology measures iron redox state in blood samples, enabling rapid detection of oxidative stress for early intervention in cardiometabolic diseases. The platform delivers results from minimal blood samples in under 5 minutes at low cost, serving both life science researchers and clinical diagnostic applications.
Differentiator
Problem solved
Functional benefit
Brands
- MarlinMR™: Proprietary microscale magnetic resonance (MMR) platform for measuring oxidative stress in blood samples for clinical diagnostics.
- BioScan-NMR™
Products and services
- MarlinMR™ Platform Proprietary oxidative stress testing platform built on LarmorBio's Microscale Magnetic Resonance (MMR) technology. Delivers results from a few drops of blood in under 5 minutes at low cost by an untrained user at point of care, measuring iron redox state in the blood microenvironment as a direct marker of oxidative stress for clinical diagnostics and metabolic disease risk assessment.
- BioScan-NMR™ Platform Next-generation nuclear magnetic resonance diagnostic system developed by LarmorBio. Licensed exclusively to Velocity Bioworks for commercial development and deployment; first commercial installation targeted for July 2026 at Velocity Bioworks' San Antonio facility. Positions the partner as a demonstration and validation site for scaled deployment.
- MMR Non-Invasive Bioprocessing Monitoring Application of LarmorBio's Microscale Magnetic Resonance relaxometry for continuous, real-time, label-free assessment of cell viability, density, and senescence in bioreactors (including HEK293 and CHO cell lines) without breaking the sterile barrier. Eliminates contamination risks from invasive sampling and enables early intervention, addressing the $30B+ annual cost of bioprocessing batch failures.
Quantifiable outcome
- Strong correlation (R2 = 0.91) between MMR measurements and percentage of viable cells in bioreactor monitoring
- +3 more outcomes
Companies that use LarmorBio
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
LarmorBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
LarmorBio partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, foundational and minor.
- Velocity BioworkscoreValion Bio's wholly owned subsidiary Velocity Bioworks secured exclusive commercial development and license agreement for BioScan-NMR platform. First commercial installation targeted for July 2026 at Velocity Bioworks' San Antonio facility. The agreement was structured at pre-institutional pricing ahead of LarmorBio's pending Series A financing, positioning both companies as co-dependent strategic partners rather than a conventional vendor-customer relationship.
- Quest DiagnosticscoreCollaboration to present clinical data at the 24th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease. CMO Michael McPhaul presented novel blood test data capturing earliest transitions in metabolic health, demonstrating early disease detection capability.
- Tan Tock Seng HospitalcoreResearch partnership for large-scale study evaluating oxidative stress as biomarker for cardiovascular risk. Study evaluating 1,500 high-risk cardiovascular patients comparing oxidative stress levels with disease outcomes. Study presented at European Atherosclerosis Society Congress demonstrating link between oxidative stress and vascular function.
- Pharmaceutical Companies (undisclosed)corePartnership with pharmaceutical company to develop early warning systems and treatments for cardiac reperfusion injury (2 million major cardiac surgeries annually in U.S.). Collaboration with leading pharmaceutical companies to explore how oxidative stress influences GLP-1 drug effectiveness.
- MIT Research Laboratory of ElectronicsfoundationalTechnology origin - LarmorBio was founded on breakthrough technology developed at MIT's Research Laboratory of Electronics and Singapore MIT Alliance for Research and Technology (SMART).
- Singapore MIT Alliance for Research and Technology (SMART)foundationalTechnology origin partnership. SMART researchers contributed to the development of microscale magnetic resonance technology including key publications on the platform capabilities.
- Duke-NUS Medical SchoolminorScientific collaboration with Yie Hou Lee, Ph.D., Scientific Director at SMART and Assistant Professor at Duke-NUS Medical School, contributing to publications on MMR technology applications in bioprocessing.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
LarmorBio competitors and assessment
Company assessmentDirect peers
- T2 Biosystems: T2 Biosystems developed T2 Magnetic Resonance (T2MR) technology for direct detection of molecular targets, pathogens, and biomarkers from patient samples. Both companies leverage proprietary magnetic resonance platforms for clinical diagnostics, making T2 the closest direct technological peer.
- Numares Health: Numares Health develops NMR-based diagnostic tests leveraging metabolomics for disease detection and monitoring. Its focus on NMR spectroscopy to identify biomarker signatures from blood is technologically analogous to LarmorBio's MMR platform for oxidative stress measurement.
Broad incumbents
- Bruker Corporation: Bruker is a global leader in NMR spectroscopy and mass spectrometry instruments used in life sciences research, biopharma, and clinical research. Bruker's broader NMR instrumentation portfolio overlaps with LarmorBio's BioScan-NMR platform in bioprocessing and research applications.
- Oxford Instruments: Oxford Instruments manufactures NMR and EPR spectroscopy systems used across research, life sciences, and industrial applications. Its benchtop NMR product line for analytical applications competes in the same technological space as LarmorBio's microscale MR platform.
- Thermo Fisher Scientific: Thermo Fisher offers a broad portfolio of analytical instruments, mass spectrometers, and laboratory diagnostic solutions across clinical and life science markets. It serves as the dominant incumbent in the analytical instrument category where LarmorBio's platform competes.
- Bio-Techne: Bio-Techne provides life science research tools, diagnostics reagents, and analytical instruments used in clinical and bioprocessing workflows. Its portfolio of protein/analytical assays and GMP-grade reagents overlaps with both LarmorBio's diagnostic and bioprocessing verticals.
- Siemens Healthineers: Siemens Healthineers is a major diagnostic and medical imaging company offering IVD platforms, lab instruments, and clinical diagnostics services. As one of the largest clinical diagnostics players, it represents the type of incumbent that could partner with or compete against LarmorBio in cardiometabolic testing.
- Abbott Diagnostics: Abbott is a global IVD leader with extensive point-of-care testing, clinical chemistry, and immunoassay platforms. Its established commercial channels in primary care and cardiometabolic testing represent both the addressable market and a competitive threat for LarmorBio's MarlinMR platform.
- Repligen: Repligen supplies bioprocessing analytics, sensors, and process analytics tools for biopharmaceutical manufacturers. Its portfolio of real-time monitoring and PAT (Process Analytical Technology) solutions directly overlaps with LarmorBio's BioScan-NMR bioprocessing application.
Emerging players
- Seer: Seer is a proteomics company developing novel biomarker discovery platforms using engineered nanoparticle technology. Its focus on novel biomarker-based insights from blood samples for early disease detection aligns thematically with LarmorBio's oxidative stress biomarker approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
LarmorBio social profiles
Digital presenceLarmorBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
LarmorBio leadership team
Management profileNumber of profiles
Profiles13 records
LarmorBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LarmorBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LarmorBio
What does LarmorBio do?
LarmorBio develops and commercializes Microscale Magnetic Resonance (MMR) technology-based diagnostic platforms — MarlinMR™ for rapid oxidative stress testing and BioScan-NMR™ for next-generation NMR diagnostics — that measure iron redox state in blood samples and enable non-invasive, label-free monitoring of cell health. The platforms deliver results from a few drops of blood in under 5 minutes at low cost, serving clinical diagnostics and life science bioprocessing applications.
Is LarmorBio a public or private company?
LarmorBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was LarmorBio founded?
LarmorBio was founded in 2021. It employs 1 to 10 people.
Where is LarmorBio based?
LarmorBio is headquartered in Aliso Viejo, United States, in the North America region.
How does LarmorBio make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are diagnostic Platform Deployment and life Science Research Services.
Who are LarmorBio's main competitors?
Direct peers on record are T2 Biosystems and Numares Health. Broad incumbents are Bruker Corporation, Oxford Instruments, Thermo Fisher Scientific, Bio-Techne, Siemens Healthineers, Abbott Diagnostics and Repligen. Seer is listed as an emerging player.
Does LarmorBio have an API?
No public API is recorded for LarmorBio.
What industry is LarmorBio in?
LarmorBio's product category is Clinical Diagnostics. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 325413 and its SIC code is 2835.